Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer [Estudio piloto para evaluar la seguridad, tolerabilidad, búsqueda de dosis y eficacia de ORY-1001 en combinación con Platino-Etopósido en pacientes con cáncer de pulmón de células pequeñas extendido y recidivante]

Trial Profile

A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer [Estudio piloto para evaluar la seguridad, tolerabilidad, búsqueda de dosis y eficacia de ORY-1001 en combinación con Platino-Etopósido en pacientes con cáncer de pulmón de células pequeñas extendido y recidivante]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs Iadademstat (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Acronyms CLEPSIDRA
  • Sponsors Oryzon
  • Most Recent Events

    • 03 Dec 2018 According to an Oryzon media release, company has announced the inclusion of the first two patients in this study
    • 03 Dec 2018 According to an Oryzon media release,Status changed from planning to recruiting.
    • 17 Oct 2018 According to an Oryzon media release, received approval of a Clinical Trial Application (CTA), from the Spanish Drug Agency (AEMPS) to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top